Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2015

Open Access 01-12-2015 | Research article

The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease

Authors: Der-Yuan Chen, Yi-Ming Chen, Chi-Chen Lin, Chia-Wei Hsieh, Yen-Ching Wu, Wei-Ting Hung, Hsin-Hua Chen, Joung-Liang Lan

Published in: BMC Musculoskeletal Disorders | Issue 1/2015

Login to get access

Abstract

Background

Accumulating evidence has demonstrated a pathogenic role of advanced glycation end products (AGEs) and receptors for AGEs (RAGE) in inflammation. Soluble RAGE (sRAGE), with the same ligands-binding capacity as full-length RAGE, acts as a “decoy” receptor. However, there has been scanty data regarding AGEs and sRAGE in adult-onset Still’s disease (AOSD). This study aimed to investigate AGEs and sRAGE levels in AOSD patients and examine their association with clinical characteristics.

Methods

Using ELISA, plasma levels of AGEs and sRAGE were determined in 52 AOSD patients, 36 systemic lupus erythematosus(SLE) patients and 16 healthy controls(HC). Their associations with activity parameters and disease courses were evaluated.

Results

Significantly higher median levels of AGEs were observed in active AOSD patients (16.75 pg/ml) and active SLE patients (14.80 pg/ml) than those in HC (9.80 pg/ml, both p < 0.001). AGEs levels were positively correlated with activity scores (r = 0.836, p < 0.001), ferritin levels (r = 0.372, p < 0.05) and CRP levels (r = 0.396, p < 0.005) in AOSD patients. Conversely, significantly lower median levels of sRAGE were observed in active AOSD patients (632.2 pg/ml) and active SLE patients (771.6 pg/ml) compared with HC (1051.7 pg/ml, both p < 0.001). Plasma sRAGE levels were negatively correlated with AOSD activity scores (r = −0.320, p < 0.05). In comparison to AOSD patients with monocyclic pattern, significantly higher AGEs levels were observed in those with polycyclic or chronic articular pattern. With treatment, AGEs levels declined while sRAGE levels increased in parallel with the decrease in disease activity.

Conclusion

The elevation of AGEs levels with concomitant decreased sRAGE levels in active AOSD patients, suggests their pathogenic role in AOSD.
Literature
1.
Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91:5710–4.CrossRefPubMedPubMedCentral
2.
Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103–13.CrossRefPubMedPubMedCentral
3.
Vytasek R, Sedova L, Vilim V. Increased concentration of two different advanced glycation end-products detected by enzyme immuno- assays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:83.CrossRefPubMedPubMedCentral
4.
Li J, Hou F, Guo Z, Shan Y, Zang X, Liu Z. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand J Immunol. 2007;66:555–62.CrossRef
5.
de Leeuw K, Graaff R, de Vries R, Dullaart RP, Smit AJ, Kallenberg CG, et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:1551–6.CrossRef
6.
Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford). 2008;47:1554–8.CrossRef
7.
8.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–5004.PubMed
9.
Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99–111.CrossRefPubMed
10.
Mosquera JA. Role of the receptor for advanced glycation end products (RAGE) in inflammation. Invest Clin. 2010;51:257–68.PubMed
11.
Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci. 2009;14:1403–13.CrossRef
12.
Martens HA, Nienhuis HL, Gross S, van der Steege G, Brouwer E, Berden JH, et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus. 2012;21:959–68.CrossRefPubMed
13.
Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949–55.CrossRefPubMedPubMedCentral
14.
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816–22.CrossRefPubMed
15.
Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–109.CrossRefPubMedPubMedCentral
16.
Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716–27.CrossRefPubMed
17.
Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004;279:50019–24.CrossRefPubMedPubMedCentral
18.
Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971–8.CrossRefPubMed
19.
Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:R817–24.CrossRefPubMedPubMedCentral
20.
Mahajan N, Dhawan V, Malik S, Jain S. Serum levels of soluble receptor for advanced glycation end products (sRAGE) in Takayasu’s arteritis. Int J Cardiol. 2010;145:589–91.CrossRefPubMed
21.
Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, Yang QR, et al. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol. 2012;75:614–22.CrossRefPubMed
22.
Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139–46.PubMed
23.
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–22.CrossRefPubMed
24.
Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogeensis, clinical manifestations, and new treatment options. Ann Med. 2015;22:1–9.
25.
Narula N, Narula T, Abril A. Swizing the clinical presentation in adult onset Still’s disease. An extensive literature review. Autoimmun Rev. 2015. [Epub ahead of print].
26.
Ruscitti P, Cipriani P, Di Benedetto P, Ciccia F, Liakouli V, Carubbi F, et al. Increased level of H-ferritin and its imbalance with L-ferritin in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the diseases. Autoimmun Rev. 2015. [Epub ahead of print].
27.
Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44:550–60.CrossRefPubMed
28.
Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–7.PubMed
29.
Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98.PubMed
30.
31.
32.
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed
33.
Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37:2369–76.CrossRefPubMed
34.
Cush JJ, Medsger TA, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still’s disease: clinical course and outcome. Arthritis Rheum. 1987;30:186–94.CrossRefPubMed
35.
Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still’s disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.CrossRef
36.
Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
37.
Bombaridier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The committee on prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.CrossRef
38.
Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14:1212–22.CrossRefPubMed
39.
Quade-Lyssy P, Kanarek AM, Baiersdörfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res. 2013;54:3052–61.CrossRefPubMedPubMedCentral
40.
Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656–66.PubMed
41.
Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation end products is decreased in patients with juvenile idopathic arthritis (ERA category) and inversely corelated with disease activity and S100A12 levels. J Rheumatol. 2011;38:1994–9.CrossRefPubMed
42.
Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009;48:1190–6.CrossRef
43.
Däbritz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, Lügering A, et al. The functional -374 T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn’s disease. Am J Gastroent Liver Physiol. 2011;300:G823–32.CrossRef
44.
Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9:287–93.CrossRefPubMed
45.
Lee SW, Park KH, Park S, Kim JH, Hong SY, Lee SK, et al. Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW) F1 mice. Arthritis Rheum. 2013;65:1902–12.CrossRefPubMed
46.
Renard C, Chappey O, Wautier MP, Nagashima M, Morser J, Scherrmann JM, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 1997;52:54–62.PubMed
47.
Chavakis T, Bierhaus A, AI-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507–15.CrossRefPubMedPubMedCentral
48.
Roy CN, Semba RD, Sun K, Bandinelli S, Varadhan R, Patel KV, et al. Circulating selenium and carboxylmethyl-lysine, an advanced glycation end products, are independent predictors of anemia in older community-dwelling adults. Nutrition. 2012;28:762–6.CrossRefPubMedPubMedCentral
Metadata
Title
The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease
Authors
Der-Yuan Chen
Yi-Ming Chen
Chi-Chen Lin
Chia-Wei Hsieh
Yen-Ching Wu
Wei-Ting Hung
Hsin-Hua Chen
Joung-Liang Lan
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2015
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-015-0569-3

Other articles of this Issue 1/2015

BMC Musculoskeletal Disorders 1/2015 Go to the issue

Research article

The effect of Astym® Therapy on muscle strength: a blinded, randomized, clinically controlled trial

Research article

Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study

Research article

Extracorporeal shock wave therapy in the treatment of primary bone marrow edema syndrome of the knee: a prospective randomised controlled study

Technical advance

High resolution MRI imaging at 9.4 Tesla of the osteochondral unit in a translational model of articular cartilage repair

Research article

Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis?

Debate

Requirements for more effective prevention of work-related musculoskeletal disorders